Current Report Filing (8-k)
January 17 2017 - 07:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): January 17, 2017
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
30 Shacham Street. P.O.B. 8324, Petach Tikva, Israel
|
|
4918103
|
(Address
of Principal Executive Offices)
|
|
(ZIP
Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 3-758-2657
22
Shacham Street. P.O.B. 8324, Petach Tikva, Israel 4918103
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01. Other Events.
On
January 17, 2017, OWC Pharmaceutical Research Corp., a Delaware corporation (the “Registrant” or “OWCP”)
released its Annual Shareholder Letter, a copy of which is attached as Exhibit 99.2 to this Form 8-K. In the Annual Shareholder
Letter, the Registrant: (i) reported on the progress it achieved during 2016 and its goals and objectives for 2017; (ii) introduced
its strong and experienced management and scientific team; (iii) introduced its plans for the administration of cannabis-based
medicine through its proprietary, cannabinoid-enriched sublingual tablet for the treatment of multiple myeloma, Post-Traumatic
Stress Disorder (PTSD) and fibromyalgia and the use of its proprietary cannabinoid-based topical cream for psoriasis; and (iv)
its success in raising equity capital while at the same time establishing business relationships for the distribution and sale
of its cannabis based medicine in the United States Sand Europe.
Reference
is made to the full text of the Annual Shareholder Letter, a copy of which is attached hereto and which is incorporated herein
in its entirety by reference.
Item
9.01 Financial Statements and Exhibits.
(a)
The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated
by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibit
No.
|
|
Description
|
99.2
|
|
Annual
Shareholder Letter dated January 17, 2017, filed herewith.
|
|
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
Date:
January 17, 2017
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Feb 2024 to Mar 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Mar 2023 to Mar 2024